N/A N=11 Physiologic Response to Glucagon at Varying Insulin Levels
Type 1 Diabetes Mellitus
Primary: Area Under the Curve for Glucose Above Baseline — 0.623; 0.59; 0.03 mg/kg glucose per mcg glucagon
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=20 Characteristics of Glargine in Type 2 Diabetics
Type 2 Diabetes
Primary: Maximum Glucose Infusion Rate — 0.3; 2.6; 5.5; 6.8 umol/kg/min — p=<0.05
Phase 2 N=20 Mini-Dose Glucagon to Treat Non-Severe Hypoglycemia
Diabetes Mellitus, Type 1
Primary: Number of Hypoglycemic Events ≥50 mg/dl 15 Minutes AND ≥ 70 mg/dl 30 Minutes After Initial Treatment — 58; 53 Hypoglycemic Events — p=0.99
Phase 1 N=16 Evaluating the Benefits of Physiologic Insulin Delivery
Type 1 Diabetes
Primary: Glucagon Response to Induced Hypoglycemia — 4.8; 8.8; 5.8; 4.2 pg/mL
Phase 1 N=22 Acute Effect of HP-211 (Axulin) on Blood Glucose and Serum Insulin Responses in Healthy Lean and Overweight Humans
Insulin Resistance, Diabetes
Primary: Percentage Change in Area Under The Curve (AUC) for Blood Glucose 0-2 Hours — 301.09; 258.66; 248.63; 274.13 mmol x min/L — p=0.1146
Early Phase 1 N=7 Transdermal Insulin Response In Healthy Volunteers
Pharmacodynamic Response to Small Doses of Insulin
Primary: Postprandial Serum Glucose in mg/dL as a Response to Small Doses (0.075 to 0.15 IUs/Kg) Human Insulin Averaged Per Subject — 3.8; -1.8; 7 mg/dL — p=0.000016
N/A N=17 Effect of Naltrexone on Counterregulatory Mechanisms in Hypoglycemia
Hypoglycemia
Primary: Glucose (mg/dL) — 56.5; 52.8; 55.0; 52.8 mg/dL
N/A N=30 Biobehavioral Mechanisms of Glucose Variability
Diabetes Mellitus, Type 1
Primary: Change Between Pre and Post Challenge Glucose Variability — 0.51; 1.62; 3.71; 0.97 score on a scale
Phase 4 N=15 Effect of Ethanol Intoxication on the Anti-Hypoglycemic Action of Glucagon
Type 1 Diabetes Mellitus
Primary: AOCGIR (Area Over the Curve for Glucose Infusion Rate) — 1996; 1981 mg*minute/dl
Phase 3 N=33 Modulation of Human Myocardial Metabolism by GLP-1 Dose Response
Type 2 Diabetes Mellitus · Healthy
Primary: Myocardial Glucose Uptake. — 7.46; 7.22; 0.05; 20.89 umol/min/100g
Phase 4 N=33 Effect of Glycemic Variability on Autonomic Tone in Hospitalized Patients With Type 2 Diabetes
Type 2 Diabetes · Inpatient
Primary: Difference Between Heart Rate Variability Between Intravenous and Subcutaneous Group — 1.0; 2.6 none (ratio) — p=0.05
N/A N=9 The Effect of Bolus Speed of Rapid-Acting Insulin Analog Absorption and Action in Individuals With Type 1 Diabetes
Type1diabetes
Primary: Time to Maximum Glucose Infusion Rate — 116.54; 172.21 minutes
N/A N=17 Insulin Secretion in Diabetes Before and After Glycemic Control
Diabetes · Hyperglycemia
Primary: ISR in Response to a Glucose Clamp and Oral Glucose Ingestion Before and After 2 Months of Insulin Treatment to Improve Average Glycemia. — 0.67; 0.75; 1.11; 0.76 pmol/min
Phase 2 N=17 PK/PD Study of U-500 Regular Insulin
Type 2 Diabetes · Insulin Resistance · High Insulin Requirements
Primary: Duration (in Hours) of 20 % Dextrose Infusion Requirement — 11; 16.5 hours
N/A N=14 Effect of Formoterol on the Counterregulatory Hormonal Response to Hypoglycemia in Type 1 Diabetes.
Type 1 Diabetes
Primary: Glucagon (pg/mL) — 76; 74; 53; 56 pg/mL
Phase 1 N=32 Effect of LY2189265 on Insulin Secretion in Response to Intravenous Glucose
Diabetes Mellitus, Type 2
Primary: Maximum Insulin Concentration (Cmax) - First Phase Response — 233; 689; 74.3; 401 picomole per liter (pmol/L) — p=<0.001
Phase 4 N=36 Aspirin Dosing in Diabetic Patients
Type 2 Diabetes Mellitus · Coronary Artery Disease
Primary: Collagen Induced Aggregation — 32 percentage of platelet aggregation
N/A N=41 Beneficial Effect of Salicylates: Insulin Action, Secretion or Clearance?
Pre Diabetes · Insulin Resistant
Primary: Quantification of Insulin Action With the Insulin Suppression Test (IST) — -3; 2 mmol/L
Phase 4 N=44 Effect of DPP4 Inhibition on Growth Hormone Secretion
Obesity
Primary: Aim 1: Stimulated Peak Growth Hormone Level — 5.2; 3.1; 1.9; 2.0 ng/ml
N/A N=12 A Study to Determine Iatrogenic Hyperinsulinemia's Contribution to Insulin Resistance and Endothelial Dysfunction in Type 1 Diabetes
Diabetes Mellitus, Type 1
Primary: Change in Insulin Sensitivity Assessed as Glucose Infusion Rates — 8.6; 8.1 mg/kg FFM/min — p=<0.01
N/A N=11 Insulin Variance Throughout the Day
Insulin Sensitivity
Primary: Difference in Glucose Tolerance Between Morning at 7:00 AM and Evening at 7:00 PM — 163; 203 mg/dl — p=0.02
Phase 2 N=12 The Beta Cell Responsiveness to Glucose-dependent Insulinotropic Polypeptide (GIP) With and Without Sulfonylurea in Patients With Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Insulin Secretion — 56766 pmol/l * 90 minutes
N/A N=10 Effect of Sitagliptin on Short-Term Metabolic Dysregulation of Oral Glucocorticoid Therapy
Pre-diabetes · Impaired Fasting Glucose · Impaired Glucose Tolerance
Primary: Insulin Sensitivity — 1835.4; 1846.0 ratio without units — p=.983
N/A N=26 Incretin Effect in People With Impaired Fasting Glucose
Obesity
Primary: Change in Endogenous Glucose Production — 1.47; 1.46; 1.44; 1.37 mg/kg/min
N/A N=41 Counter-Regulatory Impairment and the Effect of Microvascular Insulin Transfer in Type 1 Diabetes Mellitus
Diabetes Mellitus, Type 1
Primary: Maximum Epinephrine Response (LBGI Groups) — 495; 217 pg/ml
N/A N=21 Physical Training and the Incretin Effect
Healthy
Primary: Incretin Effect (the % of Insulin Secreted Due to the Release of the Intestinal Hormones Glucagon Like Peptide-1 (GLP-1 and Glucose-dependent Insulinotropic Peptide…
Phase 3 N=30 Paradoxical Stimulation of Hepatic Glucose Production With Dapagliflozin
Type II; Diabetes
Primary: Measurement of the Change in Plasma Glucose (mg/dL): Study 1 — -29; -17 mg/dl
Phase 4 N=344 Pre-Mix Insulin Lispro Treatment for Type 2 Diabetes Patients Who Consume a Light Breakfast
Diabetes Mellitus, Type 2
Primary: Baseline Adjusted Glycosylated Hemoglobin (HbA1c) at Endpoint — 7.55; 7.40 percent glycosylated hemoglobin
Phase 2 N=116 Safety and Efficacy of Combining Intranasal Insulin & Acute Exercise
Insulin · Exercise
Primary: Number of Participants With Manifestation of Any Symptom at Any Point During the Protocol — 4; 6; 6; 4 Participants
Phase 2 N=110 GPR119 Agonist for Hypoglycemia in Type 1 Diabetes
Diabetes Mellitus, Type 1
Primary: Maximal Glucagon Concentration During Hypoglycemia — 19.9; 22.5; 82.7 pg/mL